A Phase I/II Open-Label Study of ECT-001-Expanded Cord Blood Transplantation in Pediatric and Young Adult (<21year) Patients With High-Risk and Very High-Risk Myeloid Malignancies

Cord blood (CB) transplants are an option for patients lacking an HLA identical donor but are hampered by low cell dose, prolonged aplasia and high transplant related mortality. UM171, a novel and potent agonist of hematopoietic stem cell self renewal could solve this major limitation, allowing for CB's important qualities as lower risk of chronic GVHD and relapse to prevail. In previous trials (NCT02668315, NCT03913026, NCT04103879, and NCT03441958), the CB expansion protocol using the ECT-001-CB technology (UM171 molecule) has proven to be technically feasible and safe in adults.
UM171 expanded CB was associated with a prompt (D+17), robust (98%) and durable neutrophil recovery. Amongst patients who received a single UM171 CB transplant with a median follow-up of 18 months, risk of TRM (10%), grade 3-4 acute GVHD (13%) and moderate-severe chronic GVHD (2%) was low at 1 year post-transplant. Incidence of severe viral and bacterial infections was reduced and immunosuppression could be discontinued in 77% of patients at 1 year. Thus, PFS and GRFS were very promising, 72% and 59% at 12 months, 69% and 53% at 24 months, respectively, in particular accounting for a large proportion of very high-risk patients. By a 10-fold increase of CB accessibility, ECT-001-CB allowed access to smaller, better HLA matched CBs.
This new study seeks to test a similar strategy in a group of pediatric and young adult patients with high risk myeloid malignancies. 12 patients will be enrolled in the first stage of this 2-stage design protocol. If intervention is considered promising (<= 3 relapses in the first 12 patients), this study will open multicenter and be extended to a second stage (16 additional patients for a total accrual 28).

开始日期2021-12-01

申办/合作机构

ExCellThera, Inc.

[+1]

NCT04594031

/ Withdrawn临床1期

A Phase I Multicenter Study of Hematopoietic Stem Cell Transplant of ECT-001-Expanded Cord Blood With a Reduced Toxicity Conditioning Regimen in Patients With Severe Sickle Cell Disease

The application of experimental hematopoietic cell transplantation (HCT) therapy in sickle-cell disease (SCD) must strike a balance between the underlying disease severity and the possibility of a direct benefit of the treatment, particularly in pediatric populations. Clinical studies in adults with SCD have focused on interventions that prolong survival and improve the quality of life. Unlike children, adults with SCD are much more likely to have a debilitating complication. As a result, the risk/benefit ratio of HCT is very favorable in adults, particularly if an approach to HCT that defines an acceptable level of toxicity can be established.
Whereas hematopoietic stem cell transplantation (HSCT) remains the only curative treatment currently available for patients with SCD, the morbidity, the frequent irreversible damage in target organs and the mortality reported in the natural course of patients with severe SCD are strong incentives to perform HSCTs in younger age groups. For those who lack a matched related donor, CB transplant is an appealing option, but despite been less problematic, CB accessibility related to cell dose of appropriately matched cord blood unit (CBU) remains a significant issue. Through a 7-day culture process of a CBU's hematopoietic stem cell HSCs with the UM171 compound, the total cell dose is increased mitigating this limitation.
UM171-CB expansion (ECT-001-CB) allows a greater CB accessibility, the selection of better matched cords that might translate into favourable clinical outcomes as reported in previous trials, including a lower risk of graft-versus-host disease. After CB selection and ex-vivo expansion, ECT-001-CB transplant will follow a myeloablative reduced-toxicity conditioning regimen consisting of rATG, busulfan and fludarabine with doses of all agents optimized to the individual using model-based dosing and will be followed by standard supportive care and GVHD prophylaxis consisting of tacrolimus and MMF.

开始日期2021-07-13

申办/合作机构

ExCellThera, Inc.

[+1]

NCT04103879

/ Active, not recruiting临床2期

A Phase II Open-Label Study of UM171-Expanded Cord Blood Transplantation in Patients With High and Very High Risk Acute Leukemia/Myelodysplasia

Cord blood (CB) transplants are an option for patients lacking an HLA identical donor but are hampered by low cell dose, prolonged aplasia and high transplant related mortality. UM171, a novel and potent agonist of hematopoietic stem cell self renewal could solve this major limitation, allowing for CB's important qualities as lower risk of chronic GVHD and relapse to prevail. In a previous trial (NCT02668315), the CB expansion protocol using the ECT-001-CB technology (UM171 molecule) has proven to be technically feasible and safe. UM171 expanded CB was associated with a median neutrophil recovery at day (D)+18 post transplant. Amongst 22 patients who received a single UM171 CB transplant with a median follow-up of 18 months, risk of TRM (5%) and grade 3-4 acute GVHD (10%) were low. There was no moderate-severe chronic GVHD. Thus, overall and progression free survival at 12 months were impressive at 90% and 74%, respectively. The UM171 expansion protocol allowed access to smaller, better HLA matched CBs as >80% of patients received a 6-7/8 HLA matched CB. Interestingly there were patients with high-risk hematologic malignancies and multiple comorbidities (5 patients who had already failed an allogeneic transplant and 5 patients with refractory/relapsed acute leukemia/aggressive lymphoma). Despite this high risk population, progression was 20% at 12 months.
This new study seeks to test a similar strategy in a group of patients with high risk acute leukemia/myelodysplasia.

开始日期2020-11-13

申办/合作机构

ExCellThera, Inc.

[+1]

100 项与 Stem cell therapeutics (ExCellThera) 相关的临床结果

登录后查看更多信息

100 项与 Stem cell therapeutics (ExCellThera) 相关的转化医学

登录后查看更多信息

100 项与 Stem cell therapeutics (ExCellThera) 相关的专利（医药）

登录后查看更多信息

项与 Stem cell therapeutics (ExCellThera) 相关的文献（医药）

2022-05-01·Leukemia1区 · 医学

Human CD34+ very small embryonic-like stem cells can give rise to endothelial colony-forming cells with a multistep differentiation strategy using UM171 and nicotinamide acid

1区 · 医学

Letter

作者: Smadja, David M ; Ratajczak, Janina ; Domingues, Alison ; Rossi, Elisa ; Detriche, Grégoire ; Richez, Ulysse ; Blandinieres, Adeline ; Kucia, Magdalena ; Ratajczak, Mariusz Z ; Bujko, Kamila

Human CD34very small embryonic-like stem cells can give rise to endothelial colony-forming cells with a multistep differentiation strategy using UM171 and nicotinamide acid,.To develop a source of ECFC-like cells for vascular repair, the use of human induced pluripotent stem cells (iPS) and embryonic stem cells (ESCs) has been investigated.Therefore, VSELs could represent a clin. relevant alternative to iPS or ESCs, since they do not complete blastocyst development and do not form teratomas after transplantation into deficient mice.VSELs are the most primitive stem cells in bone marrow, which can give rise to different tissue committed progenitor cells from all germ layers without confounding factor of feeder cell fusion with VSELs.All in all, we demonstrate for the first time here a full in vitro differentiation of VSELs in true vasculogenic progenitor ECFCs with a chem. identified media with UM-171 and NMA added to culture from the first day of culture.Further studies need to better decipher origin of ECFCs and improve the vascular regenerative potential of VSELs by enhancing proliferative and vasculogenic potential of VSELECFCs in vitro and in vivo and obtain highly efficient production of patient-derived VSEL-ECFCs for the treatment of vascular disease.

1991-10-01·Zhonghua shen jing jing shen ke za zhi = Chinese journal of neurology and psychiatry

[Serum prolactin response to electroconvulsive therapy in patients with major depression].

Article

作者: Duan, Y

Serum prolactin (PRL) levels were determined at 30 min before and 5, 15, 30 and 60 min after the first and sixth electroconvulsive therapy (ECT-1 and ECT-6) in 12 female patients with major depression. There was a significant increase in serum PRL after ECT-1. The mean maximum PRL level was obtained at 30 min after ECT-1 and was 3.18 times of baseline level. The rate between mean maximum PRL level after and baseline before ECT-6 was 1.89 and was significantly lower than that during ECT-1. ECT-6 caused a significantly lower PRL release than did ECT-1 too. The possible mechanisms of produced these results were discussed.

项与 Stem cell therapeutics (ExCellThera) 相关的新闻（医药）

2025-06-19

·PRNewswire

Zemcelpro® (UM171 Cell Therapy) receives positive CHMP opinion for treatment of blood cancer patients without access to suitable donor cells

If approved, Zemcelpro® is expected to: increase access to donor-derived stem cell transplantation, which offers a potentially curative option for haematologic malignancies, including leukemias and myelodysplastic syndromes be the first and only therapy in the European Union with marketing authorization for adults with haematological malignancies requiring an allogeneic haematopoietic stem cell transplantation following myeloablative conditioning for whom no other type of suitable donor cells is available Approval decision from the European Commission expected within approximately two months MONTREAL, June 19, 2025 /PRNewswire/ -- ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and metabolic fitness, announced today the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending granting conditional marketing authorization for Zemcelpro® for the treatment of adults with haematological malignancies requiring an allogeneic haematopoietic stem cell transplantation following myeloablative conditioning for whom no other type of suitable donor cells is available. The European Commission (EC) is expected to make a final decision within approximately two months following CHMP recommendation, and the decision will apply to all 27 European Union (EU) Member States, Iceland, Norway and Liechtenstein. Continue Reading ExCellThera logo Zemcelpro®, also known as UM171 Cell Therapy, is a novel cryopreserved haematopoietic stem cell transplantation product containing two components, namely UM171-expanded CD34+ cells (dorocubicel) and unexpanded CD34- cells, each derived from the same cord blood unit. If approved, Zemcelpro® is expected to be the first and only therapy in the EU with marketing authorization for adults with haematological malignancies requiring an allogeneic haematopoietic stem cell transplantation following myeloablative conditioning for whom no other type of suitable donor cells is available. Every year in Europe there are over 10,000 new cases of patients with haematological malignancies, including leukemias and myelodysplastic syndromes, requiring bone marrow transplant, and a number of these patients do not have access to suitable donor cells for different reasons, including the absence or unavailability of suitably matched donors. The positive CHMP opinion was based on the conditional Marketing Authorization Application (MAA) for Zemcelpro®. Additional filings are planned for Zemcelpro® with other health authorities, including in the US, Canada, the UK, and Switzerland. "Each year, thousands of people in Europe are diagnosed with haematological malignancies requiring an allogeneic haematopoietic stem cell transplantation, and it's an upsetting reality that a number of them don't have access to suitable donor-derived stem cells," said Dr. Guy Sauvageau, CSO and Founder of ExCellThera. "With today's positive opinion, we are closer to bringing the life-changing potential of Zemcelpro® to patients with at-risk haematological malignancies in the EU," said David Millette, CEO of ExCellThera. "We are proud to bring our transformative cell therapy innovation to patients who continue to have unmet medical needs." The safety of Zemcelpro® is consistent with the well-characterized safety profile of conventional allogeneic blood stem cell transplantation for haematological malignancies following myeloablative conditioning. ExCellThera extends its sincere gratitude to the patients and investigators who have contributed to the clinical development of Zemcelpro®. About Zemcelpro® Zemcelpro®, also known as UM171 Cell Therapy, is a novel cryopreserved haematopoietic stem cell transplantation product containing two components, namely UM171-expanded CD34+ cells (dorocubicel) and unexpanded CD34- cells, each derived from the same cord blood unit. Zemcelpro®, developed by Cordex Biologics, a wholly owned subsidiary of ExCellThera, has been evaluated in 120 patients with haematologic malignancies in clinical trials in the United States, Europe and Canada. Zemcelpro® has received orphan drug designation and regenerative medicine advanced therapy (RMAT) designations from the FDA as well as orphan medicinal product designation, advanced therapy medicinal product (ATMP) classification and priority medicines (PRIME) designation from the EMA. Zemcelpro® has been tested in Phase 2 trials in patients with high and very high-risk acute leukemias and myelodysplasias who have limited treatment options with low survival outcomes and high incidence of relapse under the current standard of care, including patients with patients with TP53 mutations or other genetic abnormalities, patients requiring a second transplant, and patients with refractory or active disease. A pivotal Phase 3 trial in this patient population will be initiated as soon as possible. The use of Zemcelpro® in other patient populations, including pediatric patients and patients with non-malignant haematological diseases, is also being explored. The product is not yet approved for marketing by the EMA and remains subject to European Commission decision. Its safety and efficacy have not been established by other regulatory agencies, such as the FDA and Health Canada. About ExCellThera and UM171 Technology ExCellThera is a world leader in enhanced blood stem cell therapies. ExCellThera's proprietary Enhance™ platform for cell expansion and metabolic fitness is designed to deliver a greater dose of functional therapeutic stem cells by expanding haematopoietic stem cells (HSCs) from any source and counteracting the effects of culture or gene editing induced stress. ExCellThera partners with biopharmas to help them develop best-in-class cell and gene therapies by leveraging the technologies that form the Enhance™ platform, including the proprietary molecule UM171 which has a first-in-class mechanism of action for ex vivo expansion and metabolic fitness of HSCs. For additional information, visit excellthera.com, and follow us on LinkedIn. Logo - WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

细胞疗法上市批准临床2期孤儿药临床3期

2024-06-26

·GlobeNewswire-Health Care

ExCellThera Announces EMA’s Acceptance under Accelerated Assessment of Market Authorisation Application (MAA) for UM171 Cell Therapy for Patients with Hematological Malignancies who Lack a Readily Available Suitable Donor

- Market Authorisation Application (MAA) for UM171 Cell Therapy accepted under an accelerated assessment procedure by the European Medicines Agency (EMA), for adult patients with hematological malignancies requiring a stem cell transplant who lack a readily available suitable donor June 25, 2024 -- ExCellThera Inc. (ExCellThera), a world leader in enhanced blood stem cell expansion and therapies, announced today that the Market Authorisation Application (MAA) for UM171 Cell Therapy (INN-dorocubicel) has been accepted under an accelerated assessment procedure by the European Medicines Agency (EMA), for adult patients with hematological malignancies requiring a stem cell transplant who lack a readily available suitable donor. The EMA’s Committee for Medicinal Products for Human Use (CHMP) granted UM171 Cell Therapy accelerated assessment as it was deemed of major interest from a public health point of view. Accelerated assessment aims to reduce the timeframe for the CHMP to review a MAA compared to the standard procedure and follows the EMA granting Orphan Medicinal Product designation and access to the Priority Medicines scheme (PRIME) in 2020. “We are excited that the EMA has accepted this regulatory submission under an accelerated assessment procedure, as UM171 Cell Therapy has immense potential to help address a high unmet medical need for patients with hematological malignancies who require a stem cell transplant but lack a readily available suitable donor,” said David Millette, CEO of ExCellThera. “We now look forward to working closely with the EMA in the coming months to bring this therapy to the patients who need it.” UM171 Cell Therapy (INN-dorocubicel), developed by Cordex Biologics, a wholly owned subsidiary of ExCellThera, has been evaluated in 120 patients to treat hematologic malignancies in clinical trials in the United States, Europe and Canada. UM171 Cell Therapy has received orphan drug designation and regenerative medicine advanced therapy (RMAT) designations from the FDA as well as orphan medicinal product designation, advanced therapy medicinal product (ATMP) classification and priority medicines (PRIME) designation from the EMA. UM171 Cell Therapy has successfully completed Phase 2 trials in patients with high and very high-risk acute leukemias and myelodysplasias who have limited treatment options with low survival outcomes and high incidence of relapse under the current standard of care, including patients with refractory or active disease, patients requiring a second transplant, and patients with TP53 mutations or other genetic abnormalities. The initiation of a Phase 3 trial in this patient population is planned for the second half of 2024. The use of UM171 Cell Therapy in other patient populations, including patients with multiple myeloma, pediatric patients, and patients with non-malignant hematological diseases, is also being explored. UM171 Cell Therapy is an investigational cell therapy, and its safety and efficacy have not been established by the FDA, EMA, Health Canada or any other health authority. ExCellThera is a world leader in enhanced blood stem cell expansion. ExCellThera’s proprietary EnhanceTM platform for cell expansion and metabolic fitness is designed to deliver a greater dose of functional therapeutic stem cells by expanding HSCs from any source and counteracting the effects of culture or gene editing induced stress. ExCellThera partners with biopharmas to help them develop best-in-class cell and gene therapies by leveraging the technologies that form the EnhanceTM platform, including the proprietary molecule UM171 which has a first- and best-in-class mechanism of action for ex vivo expansion and metabolic fitness of HSCs. For additional information, visit excellthera.com, and follow us on LinkedIn. The content above comes from the network. if any infringement, please contact us to modify.

细胞疗法孤儿药加速审批

2024-01-02

·BioSpace

ExCellThera to Conduct Investor Meetings During the J.P. Morgan 42nd Annual Healthcare Conference and to Participate in Upcoming Investor Conferences

MONTREAL, Jan. 02, 2024 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), a world leader in blood stem cell therapies, announced today that its senior leaders will be holding investor meetings during the 42nd Annual J.P. Morgan Healthcare Conference, January 8-11, 2024, in San Francisco, CA, and will be participating in the following investor conferences in January: 2024 Biotech Showcase (Presentation) Presentation Date and Time: January 8, 2024 at 4:45 PM PT Speaker: David Millette, Chief Executive Officer Location: San Francisco, CA, Ballroom Franciscan D, Hilton Union Square ExCellThera will also hold one-on-one investor meetings during the 42nd Annual J.P. Morgan Healthcare Conference, January 8-11, 2024, in San Francisco, CA. To request a one-on-one meeting with ExCellThera, please contact sellinwood@kendallir.com. B Riley 4th Annual Oncology Conference (Fireside Chat) Presentation Date and Time: January 18, 2024 at 10:00 AM ET Speakers: Guy Sauvageau, Founder and Chief Scientific Officer and David Millette, Chief Executive Officer Location: Virtual About UM171 Cell Therapy UM171 Cell Therapy has been evaluated in over 100 patients to treat hematologic malignancies in clinical trials in the United States, Europe and Canada. UM171 Cell Therapy has received orphan drug designation and regenerative medicine advanced therapy (RMAT) designation from the FDA as well as orphan medicinal product designation, advanced therapy medicinal product (ATMP) classification and priority medicines (PRIME) designation from the EMA. High Unmet Medical Need UM171 Cell Therapy Patients with high and very high-risk acute leukemias and myelodysplasias, including patients with refractory or active disease, patients requiring a second transplant, and patients with TP53 mutations or other genetic abnormalities, have limited treatment options with low survival outcomes and high incidence of relapse under the current standard of care. UM171 Cell Therapy has successfully completed Phase 2 trials in high and very high-risk acute leukemias and myelodysplasias. A Phase 3 trial is planned in 2024 for UM171 Cell Therapy for the treatment of high and very high-risk acute leukemias and myelodysplasias. Patients with hematological malignancies requiring a stem cell transplant who lack a readily available suitable donor, including familial, unrelated or haploidentical donor, or cord blood of sufficient quantity. A Market Authorization Application (MAA) submission was completed and is under accelerated assessment with the European Medicines Agency (EMA) for the licensure of UM171 Cell Therapy for adult patients with hematological malignancies requiring a stem cell transplant who lack a readily available suitable donor. The use of UM171 Cell Therapy in other patient populations, including pediatric patients and patients with non-malignant hematological diseases, is also being explored. UM171 Cell Therapy is an investigational cell therapy, and its safety and efficacy have not been established by the FDA, EMA, Health Canada or any other health authority. About ExCellThera and UM171 Technology ExCellThera is a world leader in enhanced blood stem cell therapies. ExCellThera’s proprietary EnhanceTM platform for cell expansion and metabolic fitness is designed to deliver a greater dose of functional therapeutic stem cells by expanding HSCs from any source and counteracting the effects of culture or gene editing induced stress. ExCellThera partners with biopharmas to help them develop best-in-class cell and gene therapies by leveraging the technologies that form the EnhanceTM platform, including the proprietary molecule UM171 which has a first-in-class mechanism of action for ex vivo expansion and metabolic fitness of HSCs. For additional information, visit excellthera.com, and follow us on LinkedIn. Investor and Media Contact Sarah Ellinwood Kendall Investor Relations sellinwood@kendallir.com

细胞疗法孤儿药临床2期临床3期

100 项与 Stem cell therapeutics (ExCellThera) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
血液肿瘤	申请上市	欧盟	ExCellThera, Inc.	2024-06-25
髓系肿瘤	临床2期	美国	ExCellThera, Inc.	2021-12-01
骨髓增生异常综合征	临床2期	加拿大	ExCellThera, Inc.	2019-04-01
难治性急性白血病	临床2期	加拿大	ExCellThera, Inc.	2019-04-01
浆细胞白血病	临床2期	加拿大	ExCellThera, Inc.	2018-03-07
急性胸部综合征	临床1期	美国	ExCellThera, Inc.	2021-07-13
造血干细胞移植	药物发现	欧盟	ExCellThera, Inc.	2020-12-16
移植物抗宿主病	药物发现	美国	ExCellThera, Inc.	2018-12-13

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04103879 \| NCT03913026 (GlobeNewswire) 人工标引	临床2期	白血病 \| 骨髓增生异常综合征	50	UM171	遞鏇淵蓋蓋鏇選窪鬱餘(築襯網遞蓋製餘艱廠夢) = 築醖壓襯製築醖繭觸願糧壓齋鹽顧餘鑰鹽廠鹽 (廠壓壓簾艱遞餘願選醖 ) 更多	积极	2023-12-12
ASGCT2023	N/A	镰状细胞血症 CD34+ \| CD38- \| CD45RA ... 更多	-	UM171	艱窪淵齋艱選製鏇廠築(壓壓鑰範鏇蓋選襯築醖) = 觸蓋網願選簾鏇襯鑰顧鏇蓋繭製艱簾顧積構願 (遞醖選醖範齋鬱鏇鑰蓋 ) 更多	积极	2023-05-01
ASGCT2023	N/A	镰状细胞血症 CD34+ \| CD38- \| CD45RA ... 更多	-	UM171 (Control)	鏇鹽淵醖鑰夢襯簾淵觸(鑰鑰糧膚選襯製願齋糧) = 鬱齋鬱醖製網獵顧遞獵鑰鹽製鹹觸蓋顧構醖醖 (廠艱襯壓積艱獵觸繭網 )	积极	2023-05-01
Tandem Meetings ASTCT and CIBMTR2023	N/A	骨髓肿瘤	-	UM171 (Expanded Cord Blood Grafts)	鏇襯遞衊願鬱構夢廠鹽(顧繭選範齋憲鏇繭醖廠) = 鹽襯膚鑰願膚廠構蓋鹹廠鏇選築夢觸觸糧衊鏇 (製衊糧蓋築觸壓鬱遞遞 ) 更多	-	2023-02-01
Tandem Meetings ASTCT and CIBMTR2020	临床1期	造血干细胞移植	22	UM171 (Myeloablative conditioning regimen + single CB transplant)	憲鬱鹽鏇廠獵願遞廠鏇(製製廠遞製築構顧獵積) = 積廠製選製壓膚簾壓願衊繭艱鏇繭願鑰遞鑰齋 (範餘鬱範構簾鏇廠齋艱 ) 更多	积极	2020-03-01
ASGCT2019	N/A	-	-	UM171	廠齋衊構膚憲簾淵蓋糧(廠製窪網築窪網鹹製簾) = 網積鏇築窪範窪蓋鑰積築衊鹽壓製齋淵積製構 (糧壓夢衊觸鏇糧襯醖齋 )	-	2019-04-22
Tandem Meetings ASTCT and CIBMTR2018	N/A	-	17	UM171 expanded cord blood (eCB)	壓觸築繭壓醖鑰範積壓(繭夢鬱衊餘繭蓋製顧鹹) = 蓋餘簾願繭積選醖壓鬱艱淵築蓋選鑰壓遞簾壓 (廠蓋衊淵簾築範膚鏇網 ) 更多	积极	2018-03-01
Tandem Meetings ASTCT and CIBMTR2018	N/A	-	17	UM171 (Peripheral blood or marrow)	壓觸築繭壓醖鑰範積壓(繭夢鬱衊餘繭蓋製顧鹹) = 壓夢範壓遞網網窪齋糧艱淵築蓋選鑰壓遞簾壓 (廠蓋衊淵簾築範膚鏇網 )	积极	2018-03-01
ASGCT2014	N/A	-	-	UM171	鑰願餘鹹觸築夢觸築餘(製齋醖鏇齋壓蓋窪網鹽) = 遞餘遞鹹觸淵糧獵獵衊鬱壓淵繭積鹹獵構鏇艱 (壓網積鏇遞積積鏇襯艱 ) 更多	-	2014-05-01
ASGCT2014	N/A	-	-	UM171 (SR1)	鑰願餘鹹觸築夢觸築餘(製齋醖鏇齋壓蓋窪網鹽) = 蓋網遞鹽製構襯鹽獵築鬱壓淵繭積鹹獵構鏇艱 (壓網積鏇遞積積鏇襯艱 ) 更多	-	2014-05-01